Roche will take over the RALS POC information technology connectivity system.

Roche is acquiring Medical Automation Systems’ (MAS) assets associated with the RALS point-of-care (POC) information technology (IT) connectivity system as well as the names “Medical Automation Systems,” “MAS,” and “RALS.” Upon closing the transaction, the legal entity currently known as MAS will be renamed.

As part of Roche, RALS will remain a vendor-neutral IT connectivity solution, and Roche will continue to expand the number of device interfaces available, enabling customers to streamline POC management in their hospitals.  

“Information management plays an increasingly critical role to meet the growing needs of our POC customers,” notes Jack Phillips, president and CEO of Roche Diagnostics North America. “With this acquisition, we will build on our strategy to deliver integrated testing solutions to our customers.”

The RALS POC IT connectivity system is reportedly used in over 2,000 hospitals in the U.S. MAS’ IT systems was developed to improve efficiency and regulatory compliance of hospital POC programs.

“MAS and Roche have had a close partnership for over 10 years to co-market RALS for hospital blood glucose testing in the U.S.,” notes Kurt Wassenaar, CEO of MAS. “Roche is the ideal company to build upon the RALS system and deliver the next generation of information-management systems.”

Roche Diagnostics develops and commercializes innovative solutions in the field of serum-based laboratory and POC testing including CoaguChek® and ACCU-CHEK® brand products used by healthcare professionals to monitor coagulation and blood glucose at the point of care. They are currently used with the RALS information-management systems in healthcare facilities across the U.S.

“The acquisition of RALS assets is a perfect fit with our strategy to deliver market-leading IT connectivity solutions. It further complements our IT product portfolio,” states Peter Finckh, head of global platforms and support Roche Diagnostics. “With this acquisition, we gain a very talented group of people with strong expertise and domain knowledge in POC IT, which we expect to be instrumental in delivering future generations of POC IT solutions in collaboration with existing forces. It will further enable our mission to provide leading integrated testing solutions for our customers.”

Previous articleBioLineRx Nabs Rights to Santhera’s Preclinical MC-4R Cachexia Program
Next articleEcoliHub